News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
CVS Health (CVS) is back in focus after first quarter 2026 results and raised full year guidance, with management highlighting broad based strength across Aetna, Health Services, and Pharmacy & Consumer Wellness. See our latest analysis for CVS Health. After the earnings beat and guidance raise, the share price has climbed to US$90.55, with a 1 month share price return of 14.14% and a 1 year total shareholder return of 44.83%. This suggests momentum has picked up recently compared with longer...
Healthcare stocks have had a rough stretch. Rising medical costs, Medicaid pressure, and persistent skepticism about managed care margins have kept investors on edge all year. Walking into a CVS Health earnings report in that environment felt like bracing for bad news. The bad news, however, didn't ...
CVS Health (NYSE:CVS) raised its full-year 2026 adjusted earnings outlook after reporting stronger first-quarter results, with management citing improved performance at Aetna, continued execution at Caremark and resilient pharmacy operations. On the company’s first-quarter earnings call, David Joyn
Knorr-Bremse (ETR:KBX) opened 2026 with what CEO Marc Llistosella described as the company’s “best first quarter in the past 5 years,” citing margin recovery in the commercial vehicle business and a record order backlog in its rail division. Management also reiterated its full-year guidance, while n
CVS Health Corp (NYSE:CVS) shares rose about 6% on Wednesday morning after the retail pharmacy chain reported first quarter financial results that topped Wall Street expectations on both earnings and revenue. The company posted adjusted earnings per share (EPS) of $2.57, compared with analyst...